Test Price
2,800 AED✅ Home Collection Available
RNF213 Gene Susceptibility for Moyamoya Disease Type 2 (Genetic Testing) in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Laboratory (Cert: INT/EGQ/2509DA/3139)
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8 AM to 11 PM
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed genetic counselor
- Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731
- Regulatory Compliance: Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
Test Overview & Methodology
This RNF213 gene susceptibility test uses Next-Generation Sequencing (NGS) to detect pathogenic variants linked to Moyamoya disease type 2, a rare cerebrovascular disorder causing strokes in children and young adults. The analysis provides comprehensive coverage of the RNF213 gene, identifying known pathogenic variants and novel mutations with the highest diagnostic accuracy available. Results are interpreted by board-certified medical geneticists and delivered with a detailed clinical report that includes variant classification according to ACMG guidelines.
| Feature | Our Test (Precision/Method/Speed) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Diagnostic Sensitivity | 99.9% (NGS full-gene coverage) | ~95% (limited exon analysis) |
| Methodology | Next-Generation Sequencing (NGS) with advanced bioinformatics | Sanger sequencing of selected exons |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Cost (All-inclusive) | 2800 AED | ~3000 AED (often excludes genetic counselling) |
| Sample Collection | Pain-free FTA card blood drop or whole blood at home via VIP Mobile Phlebotomy | Venipuncture at lab only |
Physician Insight & Safety Protocols
"Having counselled many families regarding genetic susceptibility to Moyamoya disease, I understand the importance of clear, compassionate communication. The RNF213 gene test provides valuable information about inherited risk, but it must be interpreted within a complete clinical context including family history and neurological evaluation. Our genetic counselling team provides thorough post-test guidance to help you understand your results and make informed decisions about surveillance and prevention strategies."
— Ms. Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Advisory
Do not discontinue any prescribed medication without consulting your doctor. This genetic test result should not be used as a sole basis for treatment decisions. Always combine genetic findings with comprehensive clinical evaluation by a qualified specialist.
Safety & Exclusion Criteria
- Exclusion Criteria: None for the genetic test itself. Patients with severe bleeding disorders should inform the phlebotomist to ensure safe sample collection.
- ER Red Flags (Seek immediate emergency care): Sudden severe headache, weakness or numbness on one side of the body, slurred speech, sudden vision loss, difficulty walking – these may indicate a stroke in the context of Moyamoya disease.
Patient FAQ & Clinical Guidance
1. What does the RNF213 gene test for Moyamoya disease type 2 tell me?
This next-generation sequencing analysis detects RNF213 genetic mutations, precisely assessing Moyamoya disease type 2 predisposition. It identifies pathogenic variants in the RNF213 gene that confer susceptibility to this rare cerebrovascular condition. The result helps your neurologist or genetic specialist determine your risk and guide surveillance or family screening. Our genetic counsellors explain the findings in clear, supportive language during your post-test tele-consultation.
2. How accurate is the RNF213 genetic test at your UAE-accredited lab?
Our ISO-certified NGS ensures 99.9% diagnostic sensitivity for RNF213 mutations, meeting international clinical benchmarks. The laboratory operates under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and uses the latest bioinformatics pipelines validated against global reference datasets. We double-validate all findings with orthogonal review to eliminate false-positive calls, giving you confidence in every report.
3. How is the sample collected and when will I receive my results?
A blood-drop FTA card home collection or standard venipuncture yields RNF213 results in 3-4 weeks, including telephonic genetic counselling. A trained phlebotomist visits your home (8 AM to 11 PM) to collect a painless finger-prick blood sample or a small whole-blood tube. The sample is transported in an ISO-certified cold-chain system. You then receive a secure digital report and a dedicated tele-consultation to interpret the results, discuss implications, and plan any necessary clinical follow-up.
4. Can this test be performed on children?
Yes, the RNF213 genetic test can be performed on patients of any age, including children. For paediatric patients, the FTA card blood-drop method is particularly suitable as it is minimally invasive. Parental or guardian consent is required for minors, and our genetic counsellors ensure that families receive appropriate pre-test and post-test counselling tailored to paediatric cases.
5. How should I prepare for the test?
No special preparation is required for this genetic test. You may eat and drink normally before sample collection. We recommend bringing any relevant family medical history information to share with the genetic counsellor during your post-test consultation. Inform the phlebotomist if you have any bleeding disorders or are taking anticoagulant medications.
UAE Regulatory & Data Privacy Adherence
Regulatory & Data Privacy Framework
This diagnostic service operates in full compliance with UAE federal regulations governing clinical laboratory practice and patient data protection:
- Data Protection: Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring all genetic data is processed lawfully, securely, and with patient consent.
- Health Information Governance: Adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – guaranteeing digital health records and electronic communications meet the highest security standards.
- Medical Liability & Consent: Patient safety and informed consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring all clinical procedures are conducted with due diligence and accountability.
- DHA Licensing: All laboratory operations are conducted under DHA Facility License Number 1143, with full compliance to Dubai Healthcare City Authority quality standards.
Clinical & Logistical Metadata
| Test Name | RNF213 Gene Susceptibility for Moyamoya Disease Type 2 (Genetic Testing) |
| Price (AED) | 2800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or FTA Card Blood Spot |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Gene Coverage |
| ICD-10-CM Code | I67.5 (Moyamoya disease) |
| LOINC Code | 74832-3 (RNF213 gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians